PL4441028T3 - Sól s-oksprenololu - Google Patents
Sól s-oksprenololuInfo
- Publication number
- PL4441028T3 PL4441028T3 PL24703833.4T PL24703833T PL4441028T3 PL 4441028 T3 PL4441028 T3 PL 4441028T3 PL 24703833 T PL24703833 T PL 24703833T PL 4441028 T3 PL4441028 T3 PL 4441028T3
- Authority
- PL
- Poland
- Prior art keywords
- oxprenolol
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/32—Thermal properties
- C01P2006/33—Phase transition temperatures
- C01P2006/34—Melting temperatures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2301180.2A GB202301180D0 (en) | 2023-01-27 | 2023-01-27 | Salt of a pharmaceutical compound |
| PCT/GB2024/050208 WO2024157024A1 (en) | 2023-01-27 | 2024-01-26 | Salt of s-oxprenolol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4441028T3 true PL4441028T3 (pl) | 2025-09-01 |
Family
ID=85476401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL24703833.4T PL4441028T3 (pl) | 2023-01-27 | 2024-01-26 | Sól s-oksprenololu |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20250228799A1 (pl) |
| EP (1) | EP4441028B1 (pl) |
| JP (1) | JP2026509088A (pl) |
| KR (1) | KR20250149662A (pl) |
| CN (1) | CN120769844A (pl) |
| AU (1) | AU2024212388A1 (pl) |
| DK (1) | DK4441028T3 (pl) |
| ES (1) | ES3034394T3 (pl) |
| FI (1) | FI4441028T3 (pl) |
| GB (1) | GB202301180D0 (pl) |
| HR (1) | HRP20250842T1 (pl) |
| HU (1) | HUE071923T2 (pl) |
| IL (1) | IL322364A (pl) |
| LT (1) | LT4441028T (pl) |
| MX (1) | MX2025008528A (pl) |
| PL (1) | PL4441028T3 (pl) |
| PT (1) | PT4441028T (pl) |
| RS (1) | RS67013B1 (pl) |
| SI (1) | SI4441028T1 (pl) |
| SM (1) | SMT202500240T1 (pl) |
| WO (1) | WO2024157024A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025222169A1 (en) * | 2024-04-19 | 2025-10-23 | Faraday Pharmaceuticals, Inc. | S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101323580A (zh) * | 2008-07-25 | 2008-12-17 | 河北科技大学 | 手性芳氧丙醇胺类化合物及其盐的合成方法 |
| WO2014138814A1 (en) | 2013-03-14 | 2014-09-18 | Coats Andrew J S | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis |
| WO2014138806A1 (en) | 2013-03-14 | 2014-09-18 | Coats Andrew J S | Oxprenolol compositions for treating cancer |
-
2023
- 2023-01-27 GB GBGB2301180.2A patent/GB202301180D0/en not_active Ceased
-
2024
- 2024-01-26 HR HRP20250842TT patent/HRP20250842T1/hr unknown
- 2024-01-26 RS RS20250706A patent/RS67013B1/sr unknown
- 2024-01-26 AU AU2024212388A patent/AU2024212388A1/en active Pending
- 2024-01-26 HU HUE24703833A patent/HUE071923T2/hu unknown
- 2024-01-26 LT LTEPPCT/GB2024/050208T patent/LT4441028T/lt unknown
- 2024-01-26 FI FIEP24703833.4T patent/FI4441028T3/fi active
- 2024-01-26 EP EP24703833.4A patent/EP4441028B1/en active Active
- 2024-01-26 SM SM20250240T patent/SMT202500240T1/it unknown
- 2024-01-26 IL IL322364A patent/IL322364A/en unknown
- 2024-01-26 JP JP2025543662A patent/JP2026509088A/ja active Pending
- 2024-01-26 KR KR1020257025963A patent/KR20250149662A/ko active Pending
- 2024-01-26 WO PCT/GB2024/050208 patent/WO2024157024A1/en not_active Ceased
- 2024-01-26 ES ES24703833T patent/ES3034394T3/es active Active
- 2024-01-26 PT PT247038334T patent/PT4441028T/pt unknown
- 2024-01-26 PL PL24703833.4T patent/PL4441028T3/pl unknown
- 2024-01-26 SI SI202430004T patent/SI4441028T1/sl unknown
- 2024-01-26 CN CN202480009268.3A patent/CN120769844A/zh active Pending
- 2024-01-26 DK DK24703833.4T patent/DK4441028T3/da active
-
2025
- 2025-04-07 US US19/172,147 patent/US20250228799A1/en active Pending
- 2025-07-22 MX MX2025008528A patent/MX2025008528A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024212388A1 (en) | 2025-07-10 |
| ES3034394T3 (en) | 2025-08-18 |
| WO2024157024A1 (en) | 2024-08-02 |
| CN120769844A (zh) | 2025-10-10 |
| EP4441028B1 (en) | 2025-04-23 |
| LT4441028T (lt) | 2025-07-10 |
| GB202301180D0 (en) | 2023-03-15 |
| EP4441028A1 (en) | 2024-10-09 |
| FI4441028T3 (fi) | 2025-06-30 |
| IL322364A (en) | 2025-09-01 |
| SMT202500240T1 (it) | 2025-09-12 |
| HRP20250842T1 (hr) | 2025-09-12 |
| MX2025008528A (es) | 2025-11-03 |
| RS67013B1 (sr) | 2025-08-29 |
| DK4441028T3 (da) | 2025-06-30 |
| KR20250149662A (ko) | 2025-10-16 |
| PT4441028T (pt) | 2025-06-26 |
| HUE071923T2 (hu) | 2025-10-28 |
| US20250228799A1 (en) | 2025-07-17 |
| JP2026509088A (ja) | 2026-03-17 |
| SI4441028T1 (sl) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061482T2 (hu) | Szintézismódszer | |
| PT4058151T (pt) | Novo sal de composto de terfenilo | |
| IL304402A (en) | A useful morph form of the at-527 hemisulfate salt | |
| ES3059247T3 (en) | Inhibitors of sarm1 | |
| IL312564A (en) | Polymorphs of the hydrochloride salt of linfarezan glurate | |
| IL320297A (en) | Salt forms of IRAK4 joints | |
| PL4313945T3 (pl) | Krystaliczny bromowodorek 5-meo-dmt | |
| GB202411655D0 (en) | Application of circHIF1a | |
| KR102423280B9 (ko) | Sot-mram 면적 최적화 기법 | |
| GB202204778D0 (en) | Novel crystalline salt forms of mesembrine | |
| GB202103774D0 (en) | Detectiion of Ransomware | |
| HUE072981T2 (hu) | Azakinolinok mint CD38 gátlók | |
| LT4441028T (lt) | S-oksprenololio druska | |
| GB202207709D0 (en) | 5-chiloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt | |
| GB202110403D0 (en) | Ulodesine Salt | |
| IL304419A (en) | salt crystals | |
| IL317645A (en) | Methods for preparing tolbrutinib | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| IL277578A (en) | New salt forms of URAT-1 inhibitors | |
| GB2603328B (en) | Process for the synthesis of elagolix sodium salt and intermediates of said process | |
| GB202316444D0 (en) | Salts of opicapone | |
| CA3277900A1 (en) | Salt of s-oxprenolol | |
| CA3300217A1 (en) | Polymorph of ribociclib salt | |
| GB202215264D0 (en) | Use of urolithins | |
| GB202104272D0 (en) | Salt |